Jie Li
Jie Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Haiwen Ding
Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
1 shared publication - Liqin Tang
Department of Pharmacy The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China
1 shared publication - Peifang Li1 shared publication
- Sheng Liu1 shared publication
- Tong Tong
Pharmacy, The First Affiliated Hospital of USTC, Hefei, Anhui, China
1 shared publication - Zhaolin Chen
University of Science and Technology of China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Concurrent Intravenous Drug Administration to the Critically Ill: Compatibility of Ginkgo Biloba Extract With Frequently Used Drugs in the Neurological Intensive Care Unit
Objective: Ginkgo biloba extract (EGB), a traditional Chinese medicine extracted from the Ginkgophyta, was used to regulate various neurological disorders (NDs). Limited compatibility data exist on EGB after marketing with other drugs administered simultaneously through the Y‐site. This study aimed to determine the compatibility of EGB during simulated Y‐site administration with 35 continuous infusion drugs that are commonly administered in the neurological intensive care units ( NICU s). Methods: The compatibility of EGB with these drugs was determined using a well‐established experimental model to simulate Y‐site administration. EGB (0.35 mg/mL) was mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y‐site coadministration procedures in NICUs. All other drugs were prepared at maximum concentrations commonly administered in the clinical setting. Compatibility was assessed by visual inspection (observations of haziness, color change, or precipitate formation), the Tyndall effect, chromaticity, pH, turbidity, insoluble particles, and UV absorption at 0, 1, 2, and 4 h postmixing. Results: This study has identified 25 (71%) combinations that are compatible and 10 combinations that are incompatible within four hours. Visual changes occurred with EGB + acyclovir and EGB + ganciclovir. The turbidity of the mixed solution of EGB + calcium gluconate exceeds the specification. Binary combinations of EGB + aceglutamide, EGB + aescin sodium, EGB + amiodarone hydrochloride, EGB + fosfomycin, EGB + ganciclovir, EGB + meropenem, EGB + omeprazole, and EGB + vinpocetine had particles that grew over the limitation of the Chinese Pharmacopoeia specification. Both admixtures of EGB + acyclovir and EGB + amiodarone hydrochloride absorption at 420 nm and 550 nm exceeded the prescribed limits. Conclusion: It is strongly advised against combining EGB 0.35 mg/mL with acyclovir, aceglutamide, aescin sodium, amiodarone hydrochloride, calcium gluconate, fosfomycin sodium, ganciclovir, meropenem, or omeprazole, as well as vinpocetine. If coadministration is inevitable, a larger volume of saline (NS) or dextrose 5% in water (D5W) should be used to flush the port catheter before and after the EGB infusion to clean the lumen of the port catheter.
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Open AccessConcurrent Intravenous Drug Administration to the Critically Ill: Compatibility of Ginkgo Biloba Extract With Frequently Used Drugs in the Neurological Intensive Care Unit
Objective: Ginkgo biloba extract (EGB), a traditional Chinese medicine extracted from the Ginkgophyta, was used to regulate various neurological disorders (NDs). Limited compatibility data exist on EGB after marketing with other drugs administered simultaneously through the Y‐site. This study aimed to determine the compatibility of EGB during simulated Y‐site administration with 35 continuous infusion drugs that are commonly administered in the neurological intensive care units ( NICU s). Methods: The compatibility of EGB with these drugs was determined using a well‐established experimental model to simulate Y‐site administration. EGB (0.35 mg/mL) was mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y‐site coadministration procedures in NICUs. All other drugs were prepared at maximum concentrations commonly administered in the clinical setting. Compatibility was assessed by visual inspection (observations of haziness, color change, or precipitate formation), the Tyndall effect, chromaticity, pH, turbidity, insoluble particles, and UV absorption at 0, 1, 2, and 4 h postmixing. Results: This study has identified 25 (71%) combinations that are compatible and 10 combinations that are incompatible within four hours. Visual changes occurred with EGB + acyclovir and EGB + ganciclovir. The turbidity of the mixed solution of EGB + calcium gluconate exceeds the specification. Binary combinations of EGB + aceglutamide, EGB + aescin sodium, EGB + amiodarone hydrochloride, EGB + fosfomycin, EGB + ganciclovir, EGB + meropenem, EGB + omeprazole, and EGB + vinpocetine had particles that grew over the limitation of the Chinese Pharmacopoeia specification. Both admixtures of EGB + acyclovir and EGB + amiodarone hydrochloride absorption at 420 nm and 550 nm exceeded the prescribed limits. Conclusion: It is strongly advised against combining EGB 0.35 mg/mL with acyclovir, aceglutamide, aescin sodium, amiodarone hydrochloride, calcium gluconate, fosfomycin sodium, ganciclovir, meropenem, or omeprazole, as well as vinpocetine. If coadministration is inevitable, a larger volume of saline (NS) or dextrose 5% in water (D5W) should be used to flush the port catheter before and after the EGB infusion to clean the lumen of the port catheter.